Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 venetoclax + pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
2017-004232-11Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in multiple myeloma (MM), sponsored by AbbVie Inc.. Started May 2018; status: completed.
02
Drugs
venetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-004232-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004232-11.